The future of multiple sclerosis treatments

Catalina Coclitu, Cris S. Constantinescu, Radu Tanasescu
2016 Expert Review of Neurotherapeutics  
A note on versions: The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription. For more information, please contact eprints@nottingham.ac.uk The future of MS Treatments 2 Abstract Introduction. There are not many conditions in which the last few
more » ... ades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A number of disease modifying treatments (DMTs) are presently available for the treatment of the inflammatory phase of this disabling disease; however, the need for treating neurodegeneration and halting the progression of disability is still unmet. Areas covered: In this paper we review the available information on existing and emerging DMTs and we discuss their place within the context of different treatment strategies in MS, Expert Commentary: The future of MS treatments should include the development of new treatment strategies tackling disease progression, together with a better understanding of the side-effects and the best sequential strategy of implementation of available and emerging drugs.
doi:10.1080/14737175.2016.1243056 pmid:27682738 fatcat:chrfcspesrcczftbueqswstpqe